Barbara A Conley, Lou Staudt, Naoko Takebe, David A Wheeler, Linghua Wang, Maria F Cardenas, Viktoriya Korchina, Jean Claude Zenklusen, Lisa M McShane, James V Tricoli, Paul M Williams, Irina Lubensky, Geraldine O'Sullivan-Coyne, Elise Kohn, Richard F Little, Jeffrey White, Shakun Malik, Lyndsay N Harris, Bhupinder Mann, Carol Weil, Roy Tarnuzzer, Chris Karlovich, Brian Rodgers, Lalitha Shankar, Paula M Jacobs, Tracy Nolan, Sean M Berryman, Julie Gastier-Foster, Jay Bowen, Kristen Leraas, Hui Shen, Peter W Laird, Manel Esteller, Vincent Miller, Adrienne Johnson, Elijah F Edmondson, Thomas J Giordano, Benjamin Kim, S Percy Ivy
BACKGROUND: Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses. METHODS: Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate < 10%, or an unusually long response (e...
April 27, 2020: Journal of the National Cancer Institute